KRAS and cervical cancer: At present, it is unclear whether simultaneous mutations in KRAS and SMAD4 are enriched in HPV-negative tumors or adenocarcinoma, and collection of sufficient sample numbers to investigate this issue will be challenging because HPV-negative tumors and adenocarcinomas comprise minor subsets among cervical cancers.